INS and type 2 diabetes mellitus: The development of fixed-ratio combinations (FRCs) of GLP-1RAs and basal insulins has been a fundamental breakthrough in the therapeutic arsenal for T2D [7], although the introduction of FRCs has allowed the simplification of previously considered definitive ICTs [8].